ABSTRACf This study was perfonned to detennine whether synthetic ascorbic acid (AA) alone or in a natural citrus extract containing bioflavonoids, proteins, and carbohydrates was more bioavailable to human subjects. The effect of a single 500-mg ascorbate dose of the two fonns and a placebo citrus extract on plasma ascorbate was examined in eight fasting subjects. A comparison of the areas under the plasma concentration-time curves showed that the citrus extract was 35% more absorbed than AA (p < 0.00 1) and was more slowly absorbed than AA (p < 0.001). In six ascorbate-saturated male subjects the ascorbate in the citrus extract produced a greater ascorbate excretion than AA alone in 24-h post-dose urine (p < 0.05). Citrus extract ascorbate was less excreted than AA (p < 0.05) in 12 nonsaturated subjects. Ascorbate in the citrus extract was found to be more bioavailable than AA alone in human subjects. Am J Clin Nut' 1988;48:601-4. 
Introduction
There is now considerable general interest in vitamin C (ascorbic acid) supplementation because of recent popular books on the treatment of the common cold and cancer by synthetic ascorbic acid (abbreviated here as AA). Also, certain populations such as smokers and el-derly people are known to have low tissue levels of ascor-bate (1,2) and might benefit from supplementation. Al-though natural and synthetic ascorbic acids are chemi-cally identical, citrus fruits contain bioflavonoids such as naringin and hesperidin as well as carbohydrates and proteins that might affect the bioavailability of the ascor-bate. However, individuals who drink frozen or reconsti-tuted fruit juices are ingesting < 4 mg of total bioflavo-noids/L of fruit juice (3) , which are removed in process-ing due to their bitter taste. The view that bioflavonoids might act as compounds that reduce the need for ascorbic acid and thus affect its tissue concentration was first postulated by a French group> 35 y ago (4) . They found that the amount of ascorbate in the organs of guinea pigs was increased by the addition of bioflavonoids to the diet. Our group de-termined that a citrus extract containing ascorbic acid was more bioavailable to guinea pigs than AA alone (5) . The effect of bioflavonoids on tissue ascorbate was the subject of an extensive review (6) . Human studies, on the other hand, have been equivo-cal. A Canadian group recently found that the bioavail-ability of pure AA was slightly superior to ascorbate in orange juice (7) . A study using interluminal perfusion of human small intestine showed no difference between ascorbate in reconstituted orange juice and AA (8) . The objective of the present study was to determine the rela-tive bioavailability of a citrus extract to that of AA alone in humans.
Subjects and methods

Test solutions
The materials compared in this study were synthetic L-AA from Fisher Chemical Company (Pittsburgh, PA) and rena-tured vitamin C in citrus extract (CE), Citrus Fruit Medial>, manufactured by Grow Company (Hackensack, NJ). The pla-cebo CE was a light brown water-soluble powder containing 0.2% AA, 19.5% citrus bioflavonoids (19.0% naringin, 0.34% naringenin, and 0.17% hesperidin) and a minimum of 30% car-bohydrates and 15% protein. The CE was identical to the pla-cebo CE except that AA was added to a final concentration of 25.1 g/ 100 g as measured by a high-pressure liquid chromatography (HPLC) procedure after protein precipitation by meta-phosphoric acid (9) . The bioflavonoids were identified and ~LWF0001 602 VINSON AND BOSE quantified by HPLC (10) and were the typical flavanones of citrus fruit.
Subjects and sampling
This study was approved by the Human Subjects Committee of the University of Scranton. All subjects gave their written informed consent before participation. Eight healthy, non-smoking individuals (five males and three females) volunteered for the plasma study. The subjects ranged in age from 18-41 y with an average age of22:t 6 y. None of the subjects was taking vitamin supplements and none consumed foods high in ascor-bic acid on the day of the study. Each subject reported between 0800 and 0830 after an overnight fast for a base-line blood drawing by finger-prick sampling using an Autoletcll device (Owen Mumford Ltd, Oxford, UK). This technique was shown to give a sample ascorbate concentration equivalent to the more common venipuncture method (11) at much less risk and discomfort to the subject. The blood was collected in EDT A tubes and the plasma was separated immediately after sam-pling. In a random crossover experimental design, each subject drank either 500 mg AA, 2 g placebo CE, or 2 g CE dissolved in 50 mL of a solution of 278 mmol glucose/L. The placebo CE provided 4 mg ascorbate and the CE, 502 mg. Finger-prick samples were taken 1, 2, 3, 4, 6, and 8 h after dosing. Subjects were not allowed to eat until after the last sampling but were allowed to drink water as desired. A 0.1-mL aliquot of blood plasma was immediately mixed with an equal volume of 1.56 mol metaphosphoric acid/L and frozen at -20 .C. The next day the samples were analyzed by a fluorometric method (12) that measures unoxidized ascorbate. Bioflavonoids did not give a fluorescence with this procedure and therefore did not inter-fere. At weekly intervals the subjects ingested the other formu-lations and the sampling procedure was repeated.
Six males aged 21-41 y with an average age of26 :t 8 y vol-unteered for the first urine study. The subjects were saturated with AA in a protocol similar to that of Robinson (13) . After 2 wk of consuming 1 g AA to saturate the body stores, the sub-jects avoided ascorbic acid for 2 d before the experimental day. During the second day of this 2-d period, a 24-h urine collec-tion was made for use as a blank. After fasting overnight the subjects ingested in the morning 500 mg of ascorbate in one of the two forms, AA or CE (dissolved in 50 mL of a solution of 278 mmol glucose/L), in a random crossover experimental design. The subjects were then allowed to eat lunch and dinner while still avoiding foods high in ascorbic acid. A 24-h urine collection was made. The following day the subjects resumed taking I g AA for 5 d and then stopped for 2 d before ingesting the other form. Twenty-four-hour blank and postdose urine was collected as before. Urine was stored in plastic specimen bottles over 50 mL of 3.12 mol metaphosporic acid/L, kept refrigerated between collections, and frozen at -20 .C until analysis within 1 wk. The 24-h volume was recorded and an aliquot was taken for fluorimetric analysis of total ascorbate after reduction of dehydroascorbic acid with mercaptoethanol.
Twelve subjects (six males and six females) volunteered for the second urine study. They ranged in age from 18-41 y with an average age of22:t 6 y. A blank 24-h urine collection was made the day before dosing. After an overnight fast subjects consumed either AA, placebo CE, or CE as in the plasma study. Twenty-four-hour urine was collected as described previously. One week later another 24-h urine blank was collected. The other forms were given and the procedure was repeated. The subjects avoided foods high in ascorbic acid in their diet 1 wk before the experiment and during the week of the experiment.
TABLE I
Areas under the plasma ascorbate time-concentration curves after oral administration of 500 mg ascorbate in the form of synthetic ascorbic acid (AA) alone or in a citrus extract (arbitrary units) 
Data analysis
Areas under the plasma ascorbate concentration-time curves were measured for each individual by manual planime-try with a reproducibility of 2.5%. The points for determining the time for maximal ascorbate concentration were plotted by a cubic spline curve-fitting program on an IBM PC (model XT) computer (Armonk, NY).
Statistical comparisons of the results were made by a paired or two-sample Student's t test.
Results
The initial mean::!: SD fasting plasma ascorbate was 35.2 ::!: 13.7 #Lmol/L (range, 14.8-69.8 #Lmol/L). These are typical values of a normal population (14). There was no significant difference between male and female sub-jects, with levels of35.1 ::!: 14.2 and 35.2:!: 11.1 #Lmol/L, respectively. The extent of absorption of ascorbate was determined by comparing the areas under the plasma ascorbate concentration-time curves after administra-tion of each formulation. Because absorption of AA is dose-dependent (15), comparison of AA and CE was made at the same dose of ascorbic acid. The areas were measured for each subject and the data are shown in Table 1 . There was no significant difference between males and females for either AA or CE; therefore, the results were combined. All subjects showed a greater area under the curve for CE than for AA. The ascorbate in the CE was found to be significantly more absorbed than the AA (p < 0.001).
The average plasma ascorbate curves for the three for-mulations are shown in tween the two dose forms except at 4 h after ingestion when the CE produced a 68% greater plasma ascorbate than AA (p < 0.005). The placebo CE produced a small but significant increase in plasma ascorbate after 3 h compared with the O-h value (p < 0.05). The results of the first urine excretion study after a pre-vious saturation of body stores with ascorbate are shown in Table 2 . All six subjects showed a greater excretion of ascorbate after ingestion of CE compared with AA (p < 0.05).
Results of the second urine study of subjects who were not saturated with ascorbate are displayed in Table 3 . The placebo CE produced no net excretion of ascorbate. There was no significant difference between the male and female excretion data for AA or CE although males tended to excrete more ascorbate after AA ingestion than did females. Five of the six males and four of the six fe-males excreted more ascorbate after ingestion of AA than TABLE 2 Net 24-h urinary excretion of ascorbate after oral administration of 500 mg synthetic ascorbic acid (AA) alone or in a citrus extract to AA-saturated subjects 
Discussion
A comparison of the areas under the plasma ascorbate concentration-time curves (Table 1) allows the determi-nation of the relative bioavailability of the two forms. The ascorbate in the CE was found to be 35% more bio-available than AA alone (p < 0.001). This result is sim-ilar to the 48% greater bioavailability of CE found in our guinea pig study (8) . These findings seem to contradict an earlier human study by Pelletier and Keim (6) who found that AA plus the bioflavonoid rutin produced a slightly lower serum ascorbate increase than did AA alone. However, that study measured ascorbate 2 h postdose, at which time our data showed no significant difference between AA alone and the CE that contained bioflavonoids (Fig 1) . The area under the placebo CE curve was 9.4% of that under the CE curve. This percent-age is more than would be expected from the ascorbate in the placebo CE, which is only 0.8% of the CE ascor-bate. This result from a human study corroborates previ-ous data reviewed by Hughes and Wilson (5) that showed elevated tissue ascorbate in guinea pigs after administra-tion ofbioflavonoids. As seen in Figure 1 , the CE produced a peak plasma ascorbate concentration at a longer time interval after ingestion than did AA. This was not a dosageform difference because both CE and AA were given in solu-tion. The result indicates that the CE was more slowly absorbed than the AA. The time for ~LWF0001 maximum concen-tration for AA was 2~9 h which is nearly identical to the 2.8 h found by Zeitler et al (15) . The time for the CE was 4.1 h, similar to the 4-5 h found by other workers after ingestion of timed-release formulations of AA (13, 16) .
To use urinary-excretion data to compare the absorp-tion of the two forms of ascorbic acid, it is necessary to saturate the body stores because the retention of ascor-bate in the body is influenced by the nutritional status of the individual (13) . The fact that the subjects were satu-rated is corroborated bv the sie:nificantlv greater blank 604 VINSON AND BOSE 24-h urinary ascorbate in the saturated group than in the unsaturated group in the second urine study (158.0 :t 59.5 mg and 77.5 :t 35.2 mg, respectively [p < 0.05 by a two-sample t test]). The excretion from the saturated group is similar to that reported by Jones (16) , 237 :t 25.4 mg. The data on presaturated individuals in Ta-ble 2 confirm the plasma results that indicated that the CE was absorbed more than the AA alone. The urine results are similar to a previous study (6) which showed that AA plus rutin or fresh orange juice alone produced a greater ascorbate excretion than AA alone in presatu-rated subjects. Another report that confirmed these re-sults (16) showed that black currant juice, high in biofla-vonoids, produced a greater urinary excretion of ascor-bate than did AA alone. The second urine study (using nonsaturated subjects) produced different results from the first study. The re-sults in Table 3 demonstrate that the CE produces sig-nificantly less ascorbate excretion than AA alone in non-saturated subjects. In light of the plasma study and the first urine study, which showed increased absorption for the CE compared with AA alone, the second urine study results may be interpreted to indicate that the ascorbate in the CE is sequestered to a greater extent than AA alone in the tissues of nonsaturated subjects. The finding that the ascorbate in CE is more bioavail-able and more slowly absorbed than AA alone, ie, that it acts as a timed-release formulation, is advantageous for supplementation. The water-soluble CE does not suffer from the disadvantages of previous timed-release forms which were found to be less bioavailable than conven-tional forms of AA (17) . Although the mechanism of the greater bioavailability of the ascorbate in CE is not known, previous studies with bioflavonoids produced two possible mechanisms: enhanced absorption and sta-bilization of ascorbate (5) .
In conclusion, the ascorbate in the CE was found to be more slowly absorbed and more bioavailable than AA alone and is thus the preferred form of ascorbate for sup-plementation. II
We gratefully acknowledge the assistance of 0 Pelletier in the prepa-ration of this manuscript. The citrus extract was kindly supplied by R Koetzner of Grow Comoanv. Inc. Hackensack. NJ 07601.
